Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2010

View Archived Issues

Intercell begins phase II trial of travelers' diarrhea vaccine in India

Novartis describes adenosine analogue with activity against Dengue virus

Eisai completes acquisition of AkaRx and its thrombocytopenia drug AKR-501

Astex discloses prodrugs of Hsp90 inhibitors for the treatment of cancer

Enzon initiates phase II study of PEG-SN38 in metastatic breast cancer

Alnylam receives milestone payment from Roche related to RNAi therapeutic

Poniard highlights its goals for picoplatin for 2010

Botulinum toxin type B improves neuroleptic-induced sialorrhea

CAdVax vector system used to create Rift Valley fever virus vaccine

Novel EGFR kinase inhibitors effective against EGFR T790M mutation identified

Phase II trials of INNO-206 commence in advanced pancreatic cancer

OncoGenex receives funding for phase II study of OGX-427 in prostate cancer

Docetaxel efficacy improved by conjugation with deslorelin and nanoparticle gene therapy

Phase II data reported on liposome-entrapped paclitaxel in metastatic breast cancer

Pearl Therapeutics presents results phase IIa trial of glycopyrrolate inhalation aerosol

Vivus reports results from phase II Qnexa study in obstructive sleep apnea

Agennix presents novel protein kinase inhibitors for cancer therapy

Chroma Therapeutics claims IKK-2 inhibitors for treatment of inflammatory diseases

Actelion describes OX receptor antagonists for the treatment of sleep disorders

Icon Bioscience begins pivotal phase II/III trial of novel ophthalmic drug IBI-10090

EnVivo advances EVP-6124 into phase IIb for schizophrenia

Intellikine initiates phase I trial of anticancer agent INK-128

BioVex broadens inclusion criteria in phase III melanoma study of OncoVEX(GM-CSF)

Ono and Kyorin submit NDAs for orally disintegrating imidafenacin

Positive allosteric modulators of alpha7 nicotinic receptors in development at Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...